Search company, investor...

Savine Therapeutics

Stage

Other Investors | Alive

About Savine Therapeutics

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com

Headquarters Location

Suite 1, Level 8 15 London Circuit

ACT 2600,

Australia

Missing: Savine Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Savine Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Savine Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Savine Therapeutics is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Savine Therapeutics Patents

Savine Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/25/2001

10/26/2010

Molecular biology, RNA, DNA, Genetics

Grant

Application Date

5/25/2001

Grant Date

10/26/2010

Title

Related Topics

Molecular biology, RNA, DNA, Genetics

Status

Grant

Savine Therapeutics Frequently Asked Questions (FAQ)

  • What is Savine Therapeutics's latest funding round?

    Savine Therapeutics's latest funding round is Other Investors.

  • Who are the investors of Savine Therapeutics?

    Investors of Savine Therapeutics include ANU Connect.

  • Who are Savine Therapeutics's competitors?

    Competitors of Savine Therapeutics include BlueWillow Biologics, FluGen, Symphogen, Embera NeuroTherapeutics, Immune Design, Patheon, FirstString Research, Anacor Pharmaceuticals, Immune Targeting Systems, Bellicum Pharmaceuticals and 14 more.

Compare Savine Therapeutics to Competitors

L
Lofarma S.p.A.

nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.

I
ImmBio

ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.

BlueWillow Biologics Logo
BlueWillow Biologics

BlueWillow Biologics develops nasal vaccines and immunotherapy to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. The company's novel intranasal NanoVax adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. BlueWillow Biologics was formerly known as NanoBio. The company was founded in 1999 and is based in Ann Arbor, Michigan.

V
Vivaldi Biosciences

Developing genetically modified vaccines to protect against common seasonal influenza and emergent pandemic influenza. Formed to commercialize patented vaccine and virus technologies developed at the Mount Sinai School of Medicine, Vivaldi's program represents a approach to flu vaccine development and production and a major advance over flu vaccines available today.

V
Vaxent

Vaxent has developed a StepNovA vaccine for Group A streptococcus

P
Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.